A systematic review of case reports and series from Tandan and colleagues (61) showed that MuSK-MG patients are more responsive to RTX than AChR-positive, showing markedly decreased post-treatment antibody levels, as early as 3 months after RTX-mediated B cell depletion, and a longer clinical improvement in most patients. Here, MUSK is linked to myasthenia gravis.